The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies.

ABSTRACT: Cancer remains an elusive, highly complex disease and a global burden. Constant change by acquired mutations and metabolic reprogramming contribute to the high inter- and intratumor heterogeneity of malignant cells, their selective growth advantage, and their resistance to anticancer therapies. In the modern era of integrative biomedicine, realizing that a personalized approach could benefit therapy treatments and patients' prognosis, we should focus on cancer-driving advantageous modifications. Namely, reactive oxygen species (ROS), known to act as regulators of cellular metabolism and growth, exhibit both negative and positive activities, as do antioxidants with potential anticancer effects. Such complexity of oxidative homeostasis is sometimes overseen in the case of studies evaluating

SUBMITTER: Jaganjac M 

PROVIDER: S-EPMC7699519 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature